

Daniel J Wallace

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3593638/daniel-j-wallace-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

120
papers

8,973
citations

37
h-index

94
g-index

133
ext. papers

11,516
ext. citations

5.9
avg, IF

5.32
L-index

#	Paper	IF	Citations
120	Neutrophils Contribute to ER Stress in Lung Epithelial Cells in the Pristane-Induced Diffuse Alveolar Hemorrhage Mouse Model.. <i>Frontiers in Immunology</i> , 2022 , 13, 790043	8.4	0
119	ACR White Paper on Antimalarials and Cardiac Toxicity: Suggested Additions to Future Directions.. <i>Arthritis and Rheumatology</i> , 2022 ,	9.5	
118	Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 112	5.7	1
117	Regulation of cGAS-STING pathway - Implications for systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , 2021 , 2, 173-184	0.2	1
116	COVID-19 in patients with rheumatic disease: finally, a denominator. <i>Lancet Rheumatology</i> , 2021 , 3, e462-e463	14.2	0
115	Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE). <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 954-955	2.4	1
114	A Panel of Biomarkers Associates With Increased Risk for Cardiovascular Events in Women With Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021 , 3, 209-220	3.5	5
113	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
112	A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus. <i>ACR Open Rheumatology</i> , 2021 , 3, 116-123	3.5	3
111	Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 5379-5389	3.9	2
110	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021 , 60, 4737-4747	3.9	5
109	Does hydroxychloroquine improve patient reported outcomes in patients with lupus?. <i>Lupus</i> , 2021 , 30, 1790-1798	2.6	
108	Innovative Trials and New Opportunities in SLE. <i>Rheumatic Disease Clinics of North America</i> , 2021 , 47, 481-499	2.4	1
107	Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study. <i>Rheumatology</i> , 2021 ,	3.9	1
106	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
105	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1734-1740	9.5	7
104	Cell-bound complement activation products associate with lupus severity in SLE. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	4

103	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacept phase 2b ADDRESS II study. <i>Rheumatology</i> , 2020 , 59, 2930-2938	3.9	12
102	New Insights Into Systemic Lupus Erythematosus Therapies: 2010-2020. <i>Journal of Clinical Rheumatology</i> , 2020 ,	1.1	1
101	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020 , 72, 1800-1808	4.7	7
100	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020 , 72, 658-666	9.5	11
99	Raynaud's Phenomenon From PD-1 Immune Checkpoint Inhibition. <i>JCO Oncology Practice</i> , 2020 , 16, 701-702	3.9	0
98	Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-Induced Lupus Model. <i>Frontiers in Immunology</i> , 2020 , 11, 554725	8.4	10
97	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	14
96	Five-Year Follow-Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Community-Based Lupus Cohort. <i>Arthritis Care and Research</i> , 2020 , 72, 882-887	4.7	10
95	American Indians Have a Higher Risk of Sjögren's Syndrome and More Disease Activity Than European Americans and African Americans. <i>Arthritis Care and Research</i> , 2020 , 72, 1049-1056	4.7	5
94	Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020 , 72, 78-88	9.5	21
93	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020 , 72, 67-77	9.5	18
92	Unique Sjögren's syndrome patient subsets defined by molecular features. <i>Rheumatology</i> , 2020 , 59, 860-868	9.5	22
91	Baricitinib for systemic lupus erythematosus - AuthorsReply. <i>Lancet, The</i> , 2019 , 393, 402-403	4.0	3
90	Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1235-1241	2.4	33
89	Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America. <i>Lupus Science and Medicine</i> , 2019 , 6, e000317	4.6	11
88	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1125-1134	9.5	41
87	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019 , 58, 1259-1267	3.9	5
86	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 893-902	4.7	46

85	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
84	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488
83	A promising approach to targeting type 1 IFN in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2019 , 129, 958-961	15.9	11
82	199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study 2019 ,		2
81	Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. <i>Lupus Science and Medicine</i> , 2019 , 6, e000349	4.6	8
80	Drivers of Satisfaction With Care for Patients With Lupus. <i>ACR Open Rheumatology</i> , 2019 , 1, 649-656	3.5	2
79	A Bayesian gene network reveals insight into the JAK-STAT pathway in systemic lupus erythematosus. <i>PLoS ONE</i> , 2019 , 14, e0225651	3.7	3
78	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1010-1012	2.4	4
77	Clinical Trials in Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 79-85	2.4	
76	Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial. <i>Arthritis Care and Research</i> , 2019 , 71, 1425-1429	4.7	1
75	Sex Differences in Quality of Life in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019 , 71, 1647-1652	4.7	13
74	Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2018 , 5, e000247	4.6	10
73	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. <i>Human Molecular Genetics</i> , 2018 , 27, 2392-2404	5.6	22
72	Clinical Efficacy and Safety of Baminercept, a Lymphotoxin α Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1470-1480	9.5	35
71	Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. <i>Arthritis and Rheumatology</i> , 2018 , 70, 868-877	9.5	44
70	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018 , 57, 677-687	3.9	20
69	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1478-1487	4.7	36
68	Role of psychosocial reserve capacity in anxiety and depression in patients with systemic lupus erythematosus. <i>International Journal of Rheumatic Diseases</i> , 2018 , 21, 850-858	2.3	9

67	Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. <i>Arthritis and Rheumatology</i> , 2018 , 70, 266-276	9.5	114
66	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018 , 392, 222-231	4.0	243
65	Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus. <i>Molecular Medicine</i> , 2018 , 24, 24	6.2	9
64	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. <i>Human Molecular Genetics</i> , 2018 , 27, 3813-3824	5.6	23
63	IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. <i>JCI Insight</i> , 2018 , 3,	9.9	16
62	Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. <i>Trials</i> , 2018 , 19, 694	2.8	13
61	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 534-542	2.4	71
60	Prevalence of resting-ECG abnormalities in systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , 2017 , 36, 1311-1316	3.9	22
59	Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 153-158	2.4	30
58	MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. <i>Journal of Autoimmunity</i> , 2017 , 79, 105-111	15.5	40
57	Effect of Tobacco Smoking on The Clinical, Histopathological, and Serological Manifestations of Sjögren's Syndrome. <i>PLoS ONE</i> , 2017 , 12, e0170249	3.7	16
56	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. <i>PLoS Genetics</i> , 2017 , 13, e1006820	6.0	41
55	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017 , 8, 16021	17.4	171
54	Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2187-2192	9.5	29
53	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2017 , 69, 362-375	9.5	125
52	Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. <i>Arthritis and Rheumatology</i> , 2017 , 69, 630-642	9.5	37
51	Previous diagnosis of Sjögren's Syndrome as rheumatoid arthritis or systemic lupus erythematosus. <i>Rheumatology</i> , 2016 , 55, 1195-201	3.9	24
50	Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus. <i>Clinical Therapeutics</i> , 2016 , 38, 610-24	3.5	16

49	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1290-1300	9.5	65
48	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1932-44	9.5	27
47	Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products. <i>Lupus Science and Medicine</i> , 2016 , 3, e000127	4.6	21
46	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. <i>Clinical Immunology</i> , 2016 , 168, 25-29	9	41
45	Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2184-92	9.5	29
44	Belimumab: Where Are We Three Years After FDA Approval?. <i>Current Treatment Options in Rheumatology</i> , 2015 , 1, 42-50	1.3	
43	The evolution of drug discovery in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 616-20	8.1	32
42	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1837-47	9.5	77
41	Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. <i>Arthritis Research and Therapy</i> , 2015 , 17, 215	5.7	39
40	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1706-13	2.4	250
39	Chest pain in lupus patients: the emergency department experience. <i>Clinical Rheumatology</i> , 2015 , 34, 1969-73	3.9	2
38	Monoclonal antibodies, systemic lupus erythematosus, and pregnancy: insights from an open-label study. <i>Journal of Rheumatology</i> , 2015 , 42, 728-30	4.1	6
37	A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1309-15	9.5	76
36	Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2014 , 41, 300-9	4.1	118
35	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 183-90	2.4	205
34	Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. <i>Rheumatology</i> , 2014 , 53, 502-11	3.9	53
33	Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. <i>Blood</i> , 2013 , 122, 3020-9	2.2	83
32	Ten developments in the use of biologicals for systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2013 , 15, 337	4.9	0

31	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , 2013 , 52, 1313-22	3.9	98
30	Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3364-73		81
29	Disease-specific patient reported outcome tools for systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 56-65	5.3	93
28	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. <i>Nature Reviews Rheumatology</i> , 2012 , 8, 522-33	8.1	145
27	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2677-86		2688
26	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3918-30		944
25	High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1619-24	2.4	100
24	Advances in drug therapy for systemic lupus erythematosus. <i>BMC Medicine</i> , 2010 , 8, 77	11.4	29
23	Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2428-37		149
22	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1143-51		318
21	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1168-78		424
20	Hypothesis: bipolar illness with complaints of chronic musculoskeletal pain is a form of pseudofibromyalgia. <i>Seminars in Arthritis and Rheumatism</i> , 2008 , 37, 256-9	5.3	17
19	Are there models for predicting accelerated atherogenesis in systemic lupus erythematosus?. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 450-1		1
18	Editorial [Why is Current Rheumatology Reviews Different that Other Rheumatology Journals?]. <i>Current Rheumatology Reviews</i> , 2007 , 3, 171-171	1.6	
17	New methods for antinuclear antibody testing: does it cut costs and corners without jeopardizing clinical reliability?. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 410-1		2
16	Is mycophenolate mofetil a safe and effective treatment for patients with systemic lupus erythematosus?. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 16-7		1
15	What's new in the management of lupus since 2000?. <i>Journal of Clinical Rheumatology</i> , 2006 , 12, 307-13	1.1	4
14	The physician Hans Reiter as prisoner of war in Nuremberg: a contextual review of his interrogations (1945-1947). <i>Seminars in Arthritis and Rheumatism</i> , 2003 , 32, 208-30	5.3	19

13	Systemic lupus erythematosus. <i>Drugs of Today</i> , 2002 , 38, 259-63		1
12	Leukocytapheresis and rheumatoid arthritis: comment on the article by Hidaka et al. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2255-6		
11	The fibromyalgia syndrome. <i>Annals of Medicine</i> , 1997 , 29, 9-21	1.5	72
10	Prevalence of fibromyalgia in systemic lupus erythematosus patients: comment on the article by Middleton et al. <i>Arthritis and Rheumatism</i> , 1995 , 38, 872		3
9	The Relevance of Antimalarial Therapy with Regard to Thrombosis, Hypercholesterolemia and Cytokines in SLE. <i>Lupus</i> , 1993 , 2, 13-15	2.6	62
8	Inhibition of protein-kinase C in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: effect on spontaneous immunoglobulin production. <i>Autoimmunity</i> , 1991 , 10, 227-31	3	2
7	Use of autologous pregnancy plasma to treat a flare of juvenile rheumatoid arthritis: case report and literature review. <i>Journal of Clinical Apheresis</i> , 1987 , 3, 216-8	3.2	3
6	Thirty-four-year delayed-onset lupus nephritis: a case report. <i>Arthritis and Rheumatism</i> , 1987 , 30, 479-80		6
5	Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis. <i>Arthritis and Rheumatism</i> , 1985 , 28, 590-2		42
4	Plasmapheresis versus lymphoplasmapheresis in rheumatoid arthritis: immunologic comparisons and literature review. <i>Journal of Clinical Apheresis</i> , 1984 , 2, 184-9	3.2	7
3	Severe giant cell valvulitis in a patient with Reiter's syndrome. <i>Arthritis and Rheumatism</i> , 1982 , 25, 232-4		9
2	Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1979 , 22, 703-10		108
1	The biology of aging: 1976, an overview. <i>Journal of the American Geriatrics Society</i> , 1977 , 25, 104-11	5.6	7